BioStock: Promore Pharma’s leg ulcer treatment to reduce patient suffering

Promore Pharma's candidate ropocamptide is being developed for treatment of venous leg ulcers. This is a patient group that today largely lacks pharmaceutical treatment alternatives and Promore aims to reduce patient suffering as well as reduce the burden wound care places on the carer. For a clearer picture of the problem that Promore Pharma wants to solve, BioStock looks at how venous leg ulcers impact the lives of sufferers.

Read the full article about Promore Pharma on www.biostock.se/en/

https://www.biostock.se/en/2022/09/promore-pharma-leg-ulcer-treatment-to-reduce-patient-suffering

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se/en